A failed sterility test on a compounded sterile preparation (CSP) does not end with a retest. USP Chapter <797> requires a documented investigation before any decision about the affected lot, or any other lot compounded under the same conditions, can be made. The investigation determines whether the contamination originated in the sample or the compounding environment, and the answer drives three obligations: whether product must be recalled, whether the state board must be notified, and, for 503B outsourcing facilities, whether the failure meets the threshold for a mandatory FDA adverse event report.
The Investigation Every Failed Sterility Test Requires
USP <797> requires a facility to promptly investigate a sterility test failure: identify the recovered microorganism and evaluate the process, personnel, facility, and environmental monitoring records that could have caused the result. Investigators review the pharmacy's media fill records for the same process, since a documented, passing media fill supports the case that the failure traces to a single batch rather than a systemic problem. Matching the organism against environmental isolates helps, but a match alone does not confirm the contamination occurred during testing rather than compounding. The investigation must also assess whether other CSPs made under the same conditions were placed at risk, which determines how far the response reaches. Related FDA findings typically surface first on a Form 483, and the facility's response carries weight of its own.
The Recall Decision: When a Failure Reaches Dispensed Product
Whether the failure triggers a recall of dispensed product turns on what the investigation finds, not the test result alone. FDA's Insanitary Conditions at Compounding Facilities guidance states that when an investigation identifies specified insanitary conditions in the sterile compounding areas, the agency strongly recommends the facility recall all purportedly sterile drug it produced and cease sterile operations until conditions are corrected, regardless of whether every batch passed its own sterility test. Sterility testing has a documented limitation: contamination is not always evenly distributed through a batch, so a passing result does not rule out contamination in units never tested. A root cause traced to the environment or shared equipment typically reaches every lot compounded under those conditions, not only the one that failed.
A failed sterility test does not end with a retest. It ends with an investigation that decides how far a recall has to reach.
State Board of Pharmacy Reporting Obligations
State boards of pharmacy set the reporting rules for a sterility failure reaching dispensed product, and the rules are not uniform. Most boards have adopted USP <797> as the enforceable sterile compounding standard, and a number require pharmacies to report adverse events, recalls, or significant sterility failures directly to the board on jurisdiction-specific timelines. Separately, when FDA inspects a facility and identifies insanitary conditions, the agency has its own practice of issuing a state referral letter to the board, independent of anything the pharmacy reports. Controlling the board notification is a materially different position than first learning of it from FDA.
Federal Reporting for 503B Outsourcing Facilities
A 503B facility carries reporting obligations beyond the state board. Section 503B(b)(5) of the Food, Drug, and Cosmetic Act requires an outsourcing facility to submit adverse event reports to FDA under 21 CFR 310.305: a serious, unexpected adverse drug experience tied to a compounded product, including one traced to a sterility failure, must be reported electronically within 15 calendar days of learning of it. Failing to report is a prohibited act under section 301(ccc)(3) of the FD&C Act, and an unresolved inspection finding can escalate to an FDA warning letter. A Field Alert Report under 21 CFR 314.81(b)(1), by contrast, attaches to approved drug applications, a category compounded products fall outside of, so that obligation typically does not reach a sterility failure. A Biological Product Deviation Report applies narrower still, only to licensed biological products, uncommon for most CSPs.
Why Early Legal Counsel Is Critical
It is critical that compounding pharmacies and outsourcing facilities promptly retain experienced healthcare defense counsel upon receiving an FDA inspection, a state board inquiry, or any other government request tied to a sterility test failure. Early legal intervention can protect the facility's rights, shape how the investigation and any recall decision are documented, avoid inadvertent admissions in board or FDA correspondence, and preserve defenses that may otherwise be lost. Delaying representation can significantly affect the outcome of the matter.
How Health Law Alliance Can Help
Health Law Alliance defends compounding pharmacies and 503B facilities through sterility test failure investigations, recall decisions, and the state board and FDA reporting that follow. Our bench includes a former federal prosecutor and a former senior healthcare compliance executive, background that shapes how we evaluate a facility's root cause findings, recall scope, and reporting record. If your facility is investigating a failed sterility test, contact us for a free, confidential consultation.
